Serpentinelike Coronary Anomaly in a Male Patient in His 40s
https://jamanetwork.com/journals/jamacardiology/fullarticle/2846693
This case report describes branching coronary-cameral fistulas in a male patient in his 40s who presented with angina and elevated troponin I and pro–brain-type natriuretic peptide levels.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2846693
This case report describes branching coronary-cameral fistulas in a male patient in his 40s who presented with angina and elevated troponin I and pro–brain-type natriuretic peptide levels.
Clonal Hematopoiesis and Risk of Incident Pericarditis and Myocarditis in 2 US Biobank Cohorts
https://jamanetwork.com/journals/jamacardiology/fullarticle/2846692
This cohort study explores the association between clonal hematopoiesis of indeterminate potential and risk of incident pericarditis and myocarditis among participants in 2 large US biobanks.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2846692
This cohort study explores the association between clonal hematopoiesis of indeterminate potential and risk of incident pericarditis and myocarditis among participants in 2 large US biobanks.
Names Removed and Added to the Byline
https://jamanetwork.com/journals/jama/fullarticle/2846652
The Original Investigation titled “Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: the PDA Randomized Clinical Trial,” published on February 17, 2026, was corrected to remove and add names to the byline. “Anne Marie Reynolds, MD, MPH” was removed from the byline and “Praveen K. Chandrasekharan, MD, MS” was added where Dr Reynolds’ name had appeared. Dr Reynolds’ information was added to the “Additional Contributions” section. This article was corrected online.
https://jamanetwork.com/journals/jama/fullarticle/2846652
The Original Investigation titled “Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: the PDA Randomized Clinical Trial,” published on February 17, 2026, was corrected to remove and add names to the byline. “Anne Marie Reynolds, MD, MPH” was removed from the byline and “Praveen K. Chandrasekharan, MD, MS” was added where Dr Reynolds’ name had appeared. Dr Reynolds’ information was added to the “Additional Contributions” section. This article was corrected online.
The Pathology of Scurvy
https://jamanetwork.com/journals/jama/fullarticle/2846651
General knowledge of the pathology of scurvy dates back to Lind’s classic Treatise on the Scurvy, published in 1772. Hess has designated Barlow’s publication in 1883, establishing the identity of the scurvy of adults and of infants, as the modern milestone in the study of the disorder, so that “Barlow’s disease” is no longer looked on as a distinct entity. The theories of its etiology have been varied. For many years the potassium deficiency theory, suggested by Garrod, gained wide acceptance. That scurvy should be attributed to a lack of this element is, as Hess remarks, readily comprehensible in view of the abundance of potassium in the antiscorbutic [fruits and vegetables]. The citric acid theory had “a short but popular career,” as did the hypothesis including acidosis as the etiologic factor.…Toxins of alleged microbic origin have formed a favorite theme, almost since the birth of modern bacteriology, for exploitation in relation to the genesis of disorders of obscure origin; there has often been a sort of contest for favor in the eyes of students between the postulate of a specific detrimental bacterium and the mysterious pathogenic toxin.…Today there is all but universal acceptance of the interpretation of scurvy as an avitaminosis—an expression of the lack of the labile vitamin C in the diet.…
https://jamanetwork.com/journals/jama/fullarticle/2846651
General knowledge of the pathology of scurvy dates back to Lind’s classic Treatise on the Scurvy, published in 1772. Hess has designated Barlow’s publication in 1883, establishing the identity of the scurvy of adults and of infants, as the modern milestone in the study of the disorder, so that “Barlow’s disease” is no longer looked on as a distinct entity. The theories of its etiology have been varied. For many years the potassium deficiency theory, suggested by Garrod, gained wide acceptance. That scurvy should be attributed to a lack of this element is, as Hess remarks, readily comprehensible in view of the abundance of potassium in the antiscorbutic [fruits and vegetables]. The citric acid theory had “a short but popular career,” as did the hypothesis including acidosis as the etiologic factor.…Toxins of alleged microbic origin have formed a favorite theme, almost since the birth of modern bacteriology, for exploitation in relation to the genesis of disorders of obscure origin; there has often been a sort of contest for favor in the eyes of students between the postulate of a specific detrimental bacterium and the mysterious pathogenic toxin.…Today there is all but universal acceptance of the interpretation of scurvy as an avitaminosis—an expression of the lack of the labile vitamin C in the diet.…
Trends in Insulin Out-of-Pocket Costs Among US Medicare Beneficiaries
https://jamanetwork.com/journals/jama/fullarticle/2846650
This study reports decreasing out-of-pocket costs for insulin among Medicare beneficiaries not receiving the low-income subsidy and examines the distribution of costs by state from 2019 through 2023.
https://jamanetwork.com/journals/jama/fullarticle/2846650
This study reports decreasing out-of-pocket costs for insulin among Medicare beneficiaries not receiving the low-income subsidy and examines the distribution of costs by state from 2019 through 2023.
Caffeinated Coffee and Atrial Fibrillation
https://jamanetwork.com/journals/jama/fullarticle/2846649
To the Editor A recent study demonstrated that caffeinated coffee consumption reduced AF/atrial flutter burden over 6 months compared with caffeine abstinence. However, extrapolating these benefits to “other caffeinated products” warrants caution and may pose a public health risk. In this study, energy drinks accounted for 5% or less of caffeine sources.
https://jamanetwork.com/journals/jama/fullarticle/2846649
To the Editor A recent study demonstrated that caffeinated coffee consumption reduced AF/atrial flutter burden over 6 months compared with caffeine abstinence. However, extrapolating these benefits to “other caffeinated products” warrants caution and may pose a public health risk. In this study, energy drinks accounted for 5% or less of caffeine sources.
Caffeinated Coffee and Atrial Fibrillation
https://jamanetwork.com/journals/jama/fullarticle/2846648
To the Editor A recent trial involving 200 patients with persistent atrial fibrillation (AF) or atrial flutter after successful electrical cardioversion examined the effects of continuing caffeinated coffee intake for 6 months compared with abstinence. The study challenges long-held concerns that caffeine is inherently proarrhythmogenic. However, importantly, the investigators did not report the timing of coffee intake, a variable that may meaningfully influence caffeine’s physiologic effects and the interpretation of the trial’s findings.
https://jamanetwork.com/journals/jama/fullarticle/2846648
To the Editor A recent trial involving 200 patients with persistent atrial fibrillation (AF) or atrial flutter after successful electrical cardioversion examined the effects of continuing caffeinated coffee intake for 6 months compared with abstinence. The study challenges long-held concerns that caffeine is inherently proarrhythmogenic. However, importantly, the investigators did not report the timing of coffee intake, a variable that may meaningfully influence caffeine’s physiologic effects and the interpretation of the trial’s findings.
👍1
Colorectal Cancer Is Increasing in Younger Adults
https://jamanetwork.com/journals/jama/fullarticle/2846859
Colorectal cancer rates in the US increased by about 1% per year from 2018 to 2022, driven by cases in people younger than 65 years.
https://jamanetwork.com/journals/jama/fullarticle/2846859
Colorectal cancer rates in the US increased by about 1% per year from 2018 to 2022, driven by cases in people younger than 65 years.
Audio Highlights March 20, 2026
https://jamanetwork.com/journals/jama/fullarticle/2846953
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
https://jamanetwork.com/journals/jama/fullarticle/2846953
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
US Rolls Back Regulations on Mercury, Other Heavy Metal Air Pollutants
https://jamanetwork.com/journals/jama/fullarticle/2846852
This Medical News article discusses the health implications of recent changes to US Environmental Protection Agency rules for power plant emissions.
https://jamanetwork.com/journals/jama/fullarticle/2846852
This Medical News article discusses the health implications of recent changes to US Environmental Protection Agency rules for power plant emissions.
Could Lithium Treat Alzheimer Disease?
https://jamanetwork.com/journals/jama/fullarticle/2846853
This Medical News story discusses recent research about the possible use of lithium as an Alzheimer disease treatment, including a pilot clinical trial in people with mild cognitive impairment.
https://jamanetwork.com/journals/jama/fullarticle/2846853
This Medical News story discusses recent research about the possible use of lithium as an Alzheimer disease treatment, including a pilot clinical trial in people with mild cognitive impairment.
Tavapadon as Adjunctive Treatment for Parkinson Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2846847
This randomized clinical trial investigates if adjunctive tavapadon can improve motor control for people with Parkinson disease (PD) experiencing motor fluctuations while minimizing risk of adverse events.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2846847
This randomized clinical trial investigates if adjunctive tavapadon can improve motor control for people with Parkinson disease (PD) experiencing motor fluctuations while minimizing risk of adverse events.
Fixed-Dose Tavapadon for Early Parkinson Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2846846
The TEMPO-1 randomized clinical trial evaluates the efficacy, safety, and tolerability of tavapadon in adults with early Parkinson disease.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2846846
The TEMPO-1 randomized clinical trial evaluates the efficacy, safety, and tolerability of tavapadon in adults with early Parkinson disease.
Surveillance of Sepsis in Children—Making Every Case Count
https://jamanetwork.com/journals/jama/fullarticle/2846849
Sepsis is a leading cause of hospital admissions, mortality, and health care expenditure worldwide. It disproportionally affects very young and very old individuals. Sepsis in young individuals carries a magnified societal impact through potential years of life lost and reductions in quality-adjusted life-years. Sepsis increases the risk of functional impairment that may persist for decades, translating into sustained health care needs and reduced lifetime economic productivity. While many countries maintain public surveillance systems for common infectious diseases such as influenza, the absence of systematic sepsis surveillance obscures the full societal burden of disease, limits benchmarking of care, and hinders effective public health measures.
https://jamanetwork.com/journals/jama/fullarticle/2846849
Sepsis is a leading cause of hospital admissions, mortality, and health care expenditure worldwide. It disproportionally affects very young and very old individuals. Sepsis in young individuals carries a magnified societal impact through potential years of life lost and reductions in quality-adjusted life-years. Sepsis increases the risk of functional impairment that may persist for decades, translating into sustained health care needs and reduced lifetime economic productivity. While many countries maintain public surveillance systems for common infectious diseases such as influenza, the absence of systematic sepsis surveillance obscures the full societal burden of disease, limits benchmarking of care, and hinders effective public health measures.
❤2
National Estimates of Pediatric Sepsis in US Hospitals Using Clinical Data
https://jamanetwork.com/journals/jama/fullarticle/2846848
This cohort study assesses US incidence, mortality, and trends of sepsis in nonneonatal children using a Pediatric Sepsis Event (PSE) definition adapted from the 2024 Phoenix criteria for scalable electronic health record (EHR)–based surveillance.
https://jamanetwork.com/journals/jama/fullarticle/2846848
This cohort study assesses US incidence, mortality, and trends of sepsis in nonneonatal children using a Pediatric Sepsis Event (PSE) definition adapted from the 2024 Phoenix criteria for scalable electronic health record (EHR)–based surveillance.
Error in Author’s Name
https://jamanetwork.com/journals/jamaneurology/fullarticle/2846832
The Research Letter titled “Early Relapse Risk in Biopsy-Confirmed Primary Central Nervous System Vasculitis,” published online January 5, 2026, and in the February 2026 issue, was corrected to fix the spelling of the following author’s name: Philippe A. Bilodeau, MD. This article was corrected online.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2846832
The Research Letter titled “Early Relapse Risk in Biopsy-Confirmed Primary Central Nervous System Vasculitis,” published online January 5, 2026, and in the February 2026 issue, was corrected to fix the spelling of the following author’s name: Philippe A. Bilodeau, MD. This article was corrected online.
Pitfalls and Potential of Dementia Prevention Trials
https://jamanetwork.com/journals/jamaneurology/fullarticle/2846831
Dementia prevention is a global public health priority, with up to 45% of cases potentially attributable to modifiable risk factors over the life course. While recent landmark trials, including FINGER, SPRINT MIND, and POINTER, suggest either single- or multidomain lifestyle interventions can improve cognitive outcomes, others have shown no clear benefit, thus highlighting ongoing uncertainty in the field.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2846831
Dementia prevention is a global public health priority, with up to 45% of cases potentially attributable to modifiable risk factors over the life course. While recent landmark trials, including FINGER, SPRINT MIND, and POINTER, suggest either single- or multidomain lifestyle interventions can improve cognitive outcomes, others have shown no clear benefit, thus highlighting ongoing uncertainty in the field.
Can Transesophageal Echocardiography–Guided CPR Improve OHCA Outcomes?
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846749
Worldwide, an estimated 3.8 million persons experience an out-of-hospital cardiac arrest (OHCA) annually. In the United States, only 8.2% of individuals with an OHCA survive with a favorable neurological outcome. Despite higher rates of bystander cardiopulmonary resuscitation (CPR) and early use of automated external defibrillators, survival has only improved modestly from 14.4 to 15.2 per 100 000 person-years over the last 20 years.
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2846749
Worldwide, an estimated 3.8 million persons experience an out-of-hospital cardiac arrest (OHCA) annually. In the United States, only 8.2% of individuals with an OHCA survive with a favorable neurological outcome. Despite higher rates of bystander cardiopulmonary resuscitation (CPR) and early use of automated external defibrillators, survival has only improved modestly from 14.4 to 15.2 per 100 000 person-years over the last 20 years.
FDA Draft Guidance on Bayesian Methods in Trials
https://jamanetwork.com/journals/jama/fullarticle/2847013
This Perspective discusses the use of bayesian methods in clinical trials and the importance of having US Food and Drug Administration (FDA) guidance that provides substantive insights about the methods’ proper role.
https://jamanetwork.com/journals/jama/fullarticle/2847013
This Perspective discusses the use of bayesian methods in clinical trials and the importance of having US Food and Drug Administration (FDA) guidance that provides substantive insights about the methods’ proper role.
FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials
https://jamanetwork.com/journals/jama/fullarticle/2847012
This Perspective discusses the draft guidance for industry that the US Food and Drug Administration released on the use of bayesian methods in testing therapeutics.
https://jamanetwork.com/journals/jama/fullarticle/2847012
This Perspective discusses the draft guidance for industry that the US Food and Drug Administration released on the use of bayesian methods in testing therapeutics.